Niacin

Generic Name: Niacin

Brand Names: Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one

Drug Type: Small Molecule

Chemical Formula: C_₆H_₅NO_₂

CAS Number: 59-67-6

Unique Ingredient Identifier: 2679MF687A

Background: Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

Indication: Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of...

Associated Conditions: Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia

Associated Therapies: Dietary supplementation

Clinical Trials

Psilocybin-assisted Therapy for Alcohol Use Disorder

Phase 2

Not yet recruiting

Conditions: Alcohol Use Disorder
Alcohol Dependence
Depression
Anxiety

Interventions: Drug: Niacin
Drug: Psilocybin

First Posted Date: 2024-06-05

Last Posted Date: 2024-06-10

Lead Sponsor: University of Sydney

Target Recruit Count: 90

Registration Number: NCT06444243

A Study of Niacin Regulation

Early Phase 1

Recruiting

Conditions: Excessive Weight Gain

Interventions: Drug: Niacin

First Posted Date: 2023-12-18

Last Posted Date: 2024-06-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 32

Registration Number: NCT06175403

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

Not Applicable

Recruiting

Conditions: Diabetes Mellitus Type 2

Interventions: Procedure: Bariatric surgery
Drug: Nicotinic Acid

First Posted Date: 2023-07-07

Last Posted Date: 2024-12-09

Lead Sponsor: Université de Sherbrooke

Target Recruit Count: 40

Registration Number: NCT05934409

Locations: 🇨🇦
centre de recherche du CHUS, Sherbrooke, Quebec, Canada

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

Phase 2

Recruiting

Conditions: Post-traumatic Stress Disorder
PTSD
Alcohol Use Disorder
Alcohol Dependence
Comorbidities and Coexisting Conditions

Interventions: Behavioral: Prolonged exposure therapy
Drug: Niacin
Drug: MDMA

First Posted Date: 2023-02-02

Last Posted Date: 2023-11-07

Lead Sponsor: University of Sydney

Target Recruit Count: 120

Registration Number: NCT05709353

Locations: 🇦🇺
Turning Point, Richmond, Victoria, Australia
🇦🇺
Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Phase 2

Recruiting

Conditions: Tobacco Use Disorder

Interventions: Drug: Psilocybin
Drug: Niacin

First Posted Date: 2022-07-11

Last Posted Date: 2024-11-27

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 66

Registration Number: NCT05452772

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Sheppard Pratt, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

and more 1 locations

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

Phase 2

Completed

Conditions: Major Depressive Disorder
Depression

Interventions: Drug: Psilocybin
Drug: Niacin

First Posted Date: 2020-11-16

Last Posted Date: 2024-04-19

Lead Sponsor: Section for Affective Disorders; Northern Stockholm Psychiatry

Target Recruit Count: 35

Registration Number: NCT04630964

Locations: 🇸🇪
Northern Stockholm Spychiatry Clinic, Stockholm, Sweden

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

Phase 1

Terminated

Conditions: Perception Disturbance
Visual Suppression
Psychedelic Experiences

Interventions: Drug: Psilocybin
Drug: Niacin

First Posted Date: 2020-06-09

Last Posted Date: 2024-06-03

Lead Sponsor: University of Minnesota

Target Recruit Count: 10

Registration Number: NCT04424225

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus

Early Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Obesity

Interventions: Drug: Niacin
Drug: Saline

First Posted Date: 2019-03-08

Last Posted Date: 2024-08-06

Lead Sponsor: Mayo Clinic

Target Recruit Count: 12

Registration Number: NCT03867500

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Study of Psilocybin for Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Psilocybin
Drug: Niacin
Other: Set and Setting (SaS) Protocol

First Posted Date: 2019-03-07

Last Posted Date: 2023-06-05

Lead Sponsor: Usona Institute

Target Recruit Count: 104

Registration Number: NCT03866174

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Cedar Clinical Research, Draper, Utah, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States

and more 8 locations

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

Phase 1

Withdrawn

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: MDMA
Drug: Niacin

First Posted Date: 2018-11-26

Last Posted Date: 2024-05-17

Lead Sponsor: Yale University

Registration Number: NCT03752918

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy